Professor James Catto

MB ChB PhD FRCS(Urol)

Department of Oncology and Metabolism

Professor in Urological Surgery

j.catto@sheffield.ac.uk
+44 114 215 9002

Full contact details

Professor James Catto
Department of Oncology and Metabolism
GU19, G Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX
Profile

James Catto is Professor in Urological Surgery at the University of Sheffield and an Honorary Consultant Urological Surgeon at Sheffield Teaching Hospitals NHS Trust. He holds posts as Honorary Senior Clinical Research fellow at the University of Oxford and Honorary Clinical Professor, Division of Surgery & Interventional Science, University College London. He qualified from Leeds University in 1994 and trained in York and Sheffield, UK before a fellowship in Brisbane, Australia.

James obtained a PhD in 2004 and runs a research team investigating the biology and management of urological cancers. He was awarded the European Association of Urology best thesis prize and the Bard medal from BAUS for his PhD studies. In 2007 he visited the Johns Hopkins Medical School, The University of Chicago, Loyola University and The University of California, San Francisco as an EAU-AUA exchange fellow. In 2010, he was awarded the Crystal Matula by the EAU, the Astellas Education Foundation award in 2011 and the Golden Telescope by BAUS in 2014.

James has raised over £12.5 million in peer reviewed funding, published more than 200 primary research manuscripts, has more than 10,000 citations on Google and an H factor of 45 on Scopus. His research funding includes a GSK Clinician Scientist fellowship, a MRC Clinical Research Fellowship, and grants from The Wellcome Trust, CRUK, European Union, Royal College of Surgeons, The Urological Foundation and Yorkshire Cancer Research.

James is Editor In Chief of European Urology (2016 Impact factor 17.581). Please see the European Urology website for further details.

Research interests

James is head of the Academic Urology Unit, encompassing an NIHR Clinical Lecturers NIHR ACFs, post-docs, technicians, Research Nurses and PhD students. The team research the translational application of molecular biology to urological malignancies, in particular Bladder and Prostate Cancer, and partake in clinical trials focused on improving the care of patients with these cancers. James's particular interest is in the epigenetic alterations seen within these tumours.


Current projects

James is Chief Investigator for i). The BRAVO Feasibility study - High-grade Bladder cancer: A randomised controlled trial of Radical Cystectomy against intravesical immunotherapy (Funded by Yorkshire Cancer Research), ii). Life and Bladder Cancer: The Yorkshire Cancer Research Bladder Cancer Patient Reported Outcomes Survey. (Funded by Yorkshire Cancer Research), iii). iROC - A multicentre randomised controlled trial to compare the efficacy of Robotically Assisted Radical Cystectomy and intracorporeal urinary diversion with Open Radical Cystectomy in patients with bladder cancer (Funded by TUF), and iv). INSTIL - INvestigation of STK-01 as intra-vesical treatment for bladder cancer (Funded by CRUK).

Publications

Journal articles

Chapters

Conference proceedings papers

  • Khetrapal* P, Catto J, Norman W, Ambler G, Sarpong R, Khan MS, Thurairaja R, Tan M, Feber A, Dixon S , Goodwin L et al (2020) MP61-06 THE ROLE OF WEARABLE DEVICES AND CPET IN PREDICTING MAJOR COMPLICATIONS AFTER RADICAL CYSTECTOMY. The Journal of Urology, Vol. 203 (pp e937-e937) RIS download Bibtex download
  • Griffin JL, Wei W, Heath P & Catto JWF (2019) Low Levels of Intra-Tumour Heterogeneity in Non-Muscle Invasive Bladder Cancer. JOURNAL OF PATHOLOGY, Vol. 249 (pp S12-S12) RIS download Bibtex download
  • Sathianathen N, Omer A, Moore C, Kasivisvanathan V, van den Bergh R, Punwani S, Kastner C, Barrett T, Murphy D, Catto J , MacPherson R et al (2019) NEGATIVE PREDICTIVE VALUE OF MULTI-PARAMETRIC MRI IN DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS. JOURNAL OF UROLOGY, Vol. 201(4) (pp E341-E341) RIS download Bibtex download
  • Wymer K, Sharma V, Borah B, Catto J, Thompson RH, Karnes RJ & Boorjian S (2019) COMPARATIVE COST-EFFECTIVENESS OF ACTIVE SURVEILLANCE, RADICAL PROSTATECTOMY, AND EXTERNAL BEAM RADIOTHERAPY: LESSONS FROM PROTECT. JOURNAL OF UROLOGY, Vol. 201(4) (pp E417-E418) RIS download Bibtex download
  • Miah S, Mangera A, Osman NI, Venugopal S, Catto J & Rosario D (2019) Islam and the Urinary Stoma: A Contemporary Theological and Urological Dilemma. European Urology Focus, Vol. 5(2) (pp 301-305) RIS download Bibtex download
  • Birtle A, Johnson M, Kockelbergh R, Jr KF, Catto J, Bryan R, Jones R, Chester J, Dolling D, Donovan J , French A et al (2018) Results of POUT - A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 44-45) RIS download Bibtex download
  • Downing A, Wright P, Wilding S, Donnelly D, Hounsome L, Watson E, Wagland R, Butcher H, Kind P, Selby P , Catto J et al (2018) Patient-reported outcomes in men with advanced and localised disease: Results from the UK-wide Life After Prostate Cancer Diagnosis study. BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 11-11) RIS download Bibtex download
  • Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) Results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk non-muscle invasive bladder cancer (NMIBC). BRITISH JOURNAL OF CANCER, Vol. 119(11) (pp 39-39) RIS download Bibtex download
  • Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. ANNALS OF ONCOLOGY, Vol. 29 RIS download Bibtex download
  • Crabb SJ, Danson SJ, Dunkley D, Kalevras M, Whitehead A, Hill S, Fines K, Robb C, Bennett J, Ksiazek L , Brown SL et al (2018) SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer. Annals of Oncology, Vol. 29 (pp viii139-viii139) RIS download Bibtex download
  • Crabb SJ, Danson S, Catto J, McDowell C, Dunkley D, Huddart RA & Griffiths G (2018) SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.. Journal of Clinical Oncology, Vol. 36(15_suppl) (pp TPS4594-TPS4594) RIS download Bibtex download
  • Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, Davenport K, Feber A, Knowles M, McGrath J , Cooke P et al (2018) RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E1231-E1231) RIS download Bibtex download
  • Voskuilen CS, Seiler R, Rink M, Poyet C, Noon AP, Roghmann F, Necchi A, Aziz A, Lavollé A, Young MJ , Marks P et al (2018) Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. European Urology Focus RIS download Bibtex download
  • Mostafid H, Malde S, Mir-Kohler A, Bagnall P, Taylor J, Cresswell J & Catto J (2018) DISCHARGE OF LOW RISK NON MUSCLE INVASIVE BLADDER CANCER AFTER ONE YEAR: RESULTS OF A BAUS/BAUN NATIONAL SURVEY OF THE ADOPTION OF THE NICE BLADDER CANCER GUIDELINES RECOMMENDATIONS IN THE UK. JOURNAL OF UROLOGY, Vol. 199(4) (pp E98-E99) RIS download Bibtex download
  • Birtle A, Catto J, Johnson M, Kockelbergh R, Keeley F, Bryan R, Chester J, Jones R, Hill M, Donovan J , French A et al (2018) RESULTS OF POUT - A PHASE III RANDOMISED TRIAL OF PERI-OPERATIVE CHEMOTHERAPY VERSUS SURVEILLANCE IN UPPER TRACT UROTHELIAL CANCER (UTUC). JOURNAL OF UROLOGY, Vol. 199(4) (pp E213-E214) RIS download Bibtex download
  • Glaser A, Downing A, Wright P, Hounsome L, Kind P, Selby PJ, Wilding S, Donnelly D, Butcher H, Watson E , Richard W et al (2018) Life after prostate cancer diagnosis: One step beyond.. Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 40-40) RIS download Bibtex download
  • Birtle AJ, Chester JD, Jones RJ, Johnson M, Hill M, Bryan RT, Catto J, Donovan J, French A, Harris C , Keeley F et al (2018) Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. Journal of Clinical Oncology, Vol. 36(6_suppl) (pp 407-407) RIS download Bibtex download
  • Newton RU, Hart NH, Kenfield SA, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci LA , Plymate SR et al (2017) Exercise medicine for metastatic castrate-resistant prostate cancer: a supervised, periodised, progressive and autoregulated program combining resistance and aerobic exercise - the INTERVAL-MCRPC prescription. BJU INTERNATIONAL, Vol. 120 (pp 14-14) RIS download Bibtex download
  • Pang KH, Rosario D, Morgan S & Catto J (2017) Evaluation of a short RNA within PCA3 in the predictive role for future cancer using non-malignant prostate biopsies. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 24 (pp 144-144) RIS download Bibtex download
  • Gordon P & Catto J (2017) MP21-02 THE LONG TERM OUTCOMES FROM EARLY RE-RESECTION IN PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, Vol. 197(4S) RIS download Bibtex download
  • Leslie T, Davies L, Elliott D, Brewster S, Sooriakumaran P, Rosario D, Catto J, Dudderidge T, Ahmed H, Emberton M , Hindley R et al (2017) PD56-08 THE PART TRIAL - A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY. Journal of Urology, Vol. 197(4S) RIS download Bibtex download
  • Lewis R, Maynard L, Catto J, Cresswell J, Feber A, Griffiths TRL, Kelly J, Knight A, Knowles M, McGrath J , Penegar S et al (2016) Recruitment aids for a phase II randomised trial in low risk bladder cancer. European Journal of Surgical Oncology (EJSO), Vol. 42(11) (pp S244-S244) RIS download Bibtex download
  • Pang KH, Catto J, Wilson S, Cumberbatch M & Lesbriel S (2016) Identification of N6-adenosine methylated RNAs by m6A-seq within prostate cancer. INTERNATIONAL JOURNAL OF UROLOGY, Vol. 23 (pp 131-131) RIS download Bibtex download
  • Birtle AJ, Maynard L, Johnson M, Kockelbergh R, Lewis R, Newton M, Jones RJ, Chester JD, Blacker A, Catto J & Hall E (2016) Acute toxicity data from POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer.. Journal of Clinical Oncology, Vol. 34(15_suppl) (pp e16138-e16138) RIS download Bibtex download
  • Saad F, Kenfield SA, Chan JM, Hart NH, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci LA , Plymate SR et al (2016) Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL – MCRPC): A Movember funded multicenter, randomized, controlled phase III study.. Journal of Clinical Oncology, Vol. 34(15_suppl) (pp TPS5092-TPS5092) RIS download Bibtex download
  • Noon A, Martissen JI, Pukkala E & Catto JWF (2015) Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 11-11) RIS download Bibtex download
  • Noon A, Martissen JI, Pukkala E & Catto JWF (2015) Workplace patterns and urothelial bladder cancer phenotype - can occupation increase the risk of developing advanced disease?. BJU INTERNATIONAL, Vol. 115 (pp 8-8) RIS download Bibtex download
  • Stubendorff B, Wilhelm K, Posselt K, Catto J, Schaeffeler E, Schwab M, Hartmann A, Füssel S, Novotny V, Gajda M , Grimm M-O et al (2015) MP58-03 IDENTIFICATION OF SPECIFIC METHYLATION-BASED BIOMARKERS FOR THE ASSESSMENT OF THE METASTATIC RISK OF MUSCLE INVASIVE BLADDER CANCER. Journal of Urology, Vol. 193(4S) RIS download Bibtex download
  • Noon A, Liu Y, Shen J, Kuk C, Hermanns T, Azad A, Sweet J, Comperat E, van der Kwast TH, Catto JWF , Zlotta AR et al (2015) MP68-05 RESOLVING INTER-PATHOLOGIST VARIATION IN THE ASSIGNMENT OF GRADE USING WHOLE TRANSCRIPTOME ANALYSIS FOR PATIENTS WITH UROTHELIAL BLADDER CANCER. Journal of Urology, Vol. 193(4S) RIS download Bibtex download
  • Stubendorff B, Wilhelm K, Posselt K, Catto J, Harmann A, Fuessel S, Novotny V, Gajda M, Wunderlich H, Grimm M-O & Junker K (2014) Abstract 1358: Promoter hypermethylation of KISS1R, KiSS1, SEPT9 and CSAD as a prognostic biomarker panel to assess the metastatic potential of muscle invasive bladder tumors. Molecular and Cellular Biology RIS download Bibtex download
  • Cowling L, Varley C, Minshull T, Dickman M, Catto J & Southgate J (2014) 411: Epigenetic mechanisms of cadmium urothelial carcinogenesis. European Journal of Cancer, Vol. 50 (pp S98-S98) RIS download Bibtex download
  • Stubendorff B, Wilhelm K, Posselt K, Catto J, Hartmann A, Füssel S, Gajda M, Wunderlich H, Grimm M-O, Novotny V & Junker K (2014) MP28-06 PROMOTER HYPERMETHYLATION OF KISS1R, KISS1, SEPT9 AND CSAD AS A PROGNOSTIC BIOMARKER PANEL TO ASSESS THE METASTATIC POTENTIAL OF MUSCLE INVASIVE BLADDER TUMORS. Journal of Urology, Vol. 191(4S) RIS download Bibtex download
  • Stubendorff B, Wilhelm K, Dubey S, Dudziec E, Catto J, Gajda M, Wunderlich H, Grimm M-O & Junker K (2013) 1139 SPECIFIC CHANGES IN THE DNA METHYLATION PATTERN ENABLE AN EARLY ASSESSMENT OF THE METASTATIC RISK OF PRIMARY BLADDER TUMOURS. Journal of Urology, Vol. 189(4S) RIS download Bibtex download
  • Patel A, Catto J, Rosario D & O'Brien T (2013) 1295 SNAPSHOT OF TRANSURETHRAL RESECTION OF NEW BLADDER TUMOURS IN THE UK AUDIT (STUKA). Journal of Urology, Vol. 189(4S) RIS download Bibtex download
  • De Alejandro Montalvo J, Panoutsos G, Mahfouf M & Catto JW (2013) Radial basis function neural-fuzzy model for microarray signature identification. BIOINFORMATICS 2013 - Proceedings of the International Conference on Bioinformatics Models, Methods and Algorithms (pp 134-139) RIS download Bibtex download
  • Melling G, Hinsely EE, Catto JWF & Lambert DW (2012) 359 MicroRNA-145 Inhibits Myofibroblast Transdifferentiation by Regulating Extracellular Proteoglycan Versican. European Journal of Cancer, Vol. 48 (pp S87-S87) RIS download Bibtex download
  • Patel A, Fowler S, Rosario D, Catto J & O'Brien T (2012) Snapshot of transurethral resection in the UK audit (STUKA). BJU INTERNATIONAL, Vol. 109 (pp 34-34) RIS download Bibtex download
  • Blick C, Ramachandran A, Cranston D, Catto J & Harris AL (2012) Hypoxia regulated miRNAs in bladder cancer. BJU INTERNATIONAL, Vol. 109 (pp 25-25) RIS download Bibtex download
  • Stubendorff B, Dudziec E, Catto J, Sanjmyatav J, Gajda M, Wunderlich H, Grimm M-O & Junker K (2012) 1058 DIFFERENCES IN DNA METHYLATION PATTERN OF PRIMARY BLADDER TUMOURS CORRELATE WITH THEIR METASTATIC POTENTIAL. Journal of Urology, Vol. 187(4S) RIS download Bibtex download
  • Miah S, Dudziec E, Rosario D, Hamdy F & Catto J (2011) The utilisation of microrna in urine samples as a potential diagnostic and prognostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E1-E2) RIS download Bibtex download
  • Khan KS, Glover M, Blizard S, Miah S, Rosario DP & Catto JW (2011) Role of expression of microrna machinery in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98(6) (pp E2-E2) RIS download Bibtex download
  • Ziegler M, Catto J, Riggs T, Gates E, Grodsky M & Wasvary H (2011) PREOPERATIVE HYPERGLYCEMIA AND DIABETES AS RISK FACTORS FOR ANASTOMOTIC LEAK FOLLOWING COLECTOMY: ANALYSIS FROM THE MICHIGAN SURGICAL QUALITY COLLABORATIVE (MSQC).. DISEASES OF THE COLON & RECTUM, Vol. 54(5) (pp E43-E44) RIS download Bibtex download
  • Stubendorff B, Dudziec E, Bourghol G, Catto J, Gajda M, Wunderlich H, Junker K & Grimm M-O (2011) 869 A SPECIFIC DNA METHYLATION PATTERN DISTINGUISHES BETWEEN METASTATIC AND NON-METASTATIC BLADDER CANCERS. Journal of Urology, Vol. 185(4S) RIS download Bibtex download
  • Miah SM, Dudziec E, Rosario D, Hamdy F & Catto J (2011) Urinary MicroRNAs as a diagnostic biomarker in bladder cancer. BRITISH JOURNAL OF SURGERY, Vol. 98 (pp 52-52) RIS download Bibtex download
  • Miah S, Dudziec E, Rosario D, Hamdy F & Catto J (2010) Optimisation of microRNA extraction from urine samples with a view for a diagnostic and prognostic test for bladder cancer. BJU INTERNATIONAL, Vol. 106(1) (pp 55-55) RIS download Bibtex download
  • Khan KS, Glover M, Blizard S, Miah S, Rosario DJ & Catto JW (2010) Differential expression of microRNA processing machinery in Urothelial Carcinoma. BJU INTERNATIONAL, Vol. 106(1) (pp 54-54) RIS download Bibtex download
  • Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, De la Taille A , Rozet F et al (2007) Molecular diagnosis of localized prostate cancer by quantitative methylation-specific PCR gene patterns in urine cells obtained by prostate massage. JOURNAL OF UROLOGY, Vol. 177(4) (pp 95-95) RIS download Bibtex download
  • Catto JW, Yates D, Rehman I, Meuth M, Abbod MF, Linkens D & Hamdy FC (2007) Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation. JOURNAL OF UROLOGY, Vol. 177(4) (pp 295-296) RIS download Bibtex download
  • Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Gattegno B, Chartier-Kastler E , Richard F et al (2007) Compared performance of microsatellite and methylation urinalysis in predicting recurrence in transitional cell carcinoma and definition of a diagnostic panel of markers by bayesian network analysis. JOURNAL OF UROLOGY, Vol. 177(4) (pp 296-296) RIS download Bibtex download
  • Catto JW, Abbod MF, Linkens D, Wild PJ, Herr A, Pilarsky C, Wissman C, Hartmann A & Hamdy FC (2007) Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression. JOURNAL OF UROLOGY, Vol. 177(4) (pp 297-298) RIS download Bibtex download
  • Van Oers JMM, Zwarthoff EC, Rehman I, Azzouzi A-R, Cussenot O, Meuth M, Hamdy FC & Catto JWF (2006) FGFR3 mutations have different effects on disease course in tumors from the bladder, ureter, and renal pelvis. CANCER RESEARCH, Vol. 66(8) RIS download Bibtex download
  • Hartmann A, Catto JW, Van Oers J, Burger M, Stoehr R, Wild PJ, Cussenot O, Azzouzi A-R, Meuth M, Hamdy FC & Zwarthoff E (2006) FGFR3 mutations in upper urinary tract tumors are independent from microsatellite instability and associated with favorable outcome and a lower rate of bladder cancer recurrence. CANCER RESEARCH, Vol. 66(8) RIS download Bibtex download
  • Yates DR, Rehman I, Meuth M, Cross S, Hamdy FC & Catto JW (2006) A gene promoter hypermethylation panel to detect transitional cell carcinoma (TCC) of the bladder. CANCER RESEARCH, Vol. 66(8) RIS download Bibtex download
  • Catto J, Rehman I, Dhawan D, Meuth M & Hamdy FC (2006) Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target. JOURNAL OF UROLOGY, Vol. 175(4) (pp 197-197) RIS download Bibtex download
  • Abbod MF, Catto JWF, Linkens DA, Wild PJ, Herr A, Wissmann C, Pilarsky C, Hartmann A, Hamdy FC & IEEE (2006) Artificial intelligence technique for gene expression profiling of urinary bladder cancer. 2006 3RD INTERNATIONAL IEEE CONFERENCE INTELLIGENT SYSTEMS, VOLS 1 AND 2 (pp 634-639) RIS download Bibtex download
  • Cross SS, Hollingbury FE, Lippitt JM, Catto JW, Hamdy EC & Winder SJ (2005) beta-dystroglycan is constitutively expressed at the intercellular junctions of epithelial cells and this expression is frequently absent in common cancers. JOURNAL OF PATHOLOGY, Vol. 205 (pp 6-6) RIS download Bibtex download
  • Rehman I, Azzouzi AR, Catto J, Allen S, Cross S, Feeley K, Eaton C, Meuth M & Hamdy FC (2004) Proteomic analysis of voided urine following prostatic massage reveals tumour specific alterations. JOURNAL OF UROLOGY, Vol. 171(4) (pp 286-286) RIS download Bibtex download
  • Connelly J & Gatto J (1995) Increasing aircraft survivability through explosives detection. Aircraft Engineering, Technology, and Operations Congress RIS download Bibtex download
Teaching activities

James teaches undergraduate medical students weekly and organises various uro-oncology study days for post-graduate urologists and surgeons. James is an educational supervisor to three trainee urologist and PhD mentor to 8 students.

Professional activities

James is a member of the NCRI-CSG for Bladder and Kidney cancer, the EAU Scientific Congress Office and specialises in Uro-Oncology. He was part of the NICE Bladder Cancer Guideline development panel. James is on the Trial Steering Groups for i). Life after prostate cancer (Funded by Prostate cancer UK and Movember. ii). VANCE01 - A randomized phase I study to determine the safety and immunogenicity of ChAd-MVA vaccination compared to MVA alone with and without low dose cyclophosphamide in low and intermediate risk localised prostate cancer (Funded by European Union(, iii). POUT - A phase III randomised trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (Funded by CRUK), iv). BladderPath - Image directed Redesign of Bladder Cancer Treatment Pathways (Funded by NIHR-HTA), and v). CALIBER - A phase II randomised feasibility study of Chemoresection and surgicAl management in Low rIsk non muscle invasive Bladder cancer (Funded by CRUK).